October 7, 2022

Cutaneous Squamous-cell Carcinoma Study Finds Complete Response to Immunotherapy in More than Half of Patients

Majority of patients achieve complete pathologic response after four-dose cemiplimab therapy

22-CNR-3257217-CQD-Hero-Dr Geiger650x450

51% of patients with resectable cutaneous squamous-cell carcinoma achieved a pathological complete response and 13% achieved a pathological major response to the anti–programmed cell death 1 (PD-1) monoclonal antibody cemiplimab, according to recent findings published in the New England Journal of Medicine.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The most provocative takeaway was that after four dose of the treatment, half of the patients had a complete pathologic response,” says Jessica Geiger, MD, study co-author and medical oncologist specializing in head and neck and skin cancers at Cleveland Clinic. “The study highlights the importance that we may want to consider immunotherapy prior to moving to surgery or in place of surgery or radiation for a great deal of the patient population.”

Though it has long been known that the medication is effective for recurrent or metastatic cutaneous squamous cell carcinoma that is not amenable to surgery or radiation therapy, a confirmatory study was needed to validate its efficacy for resectable cutaneous squamous-cell carcinoma. If found early, the disease has historically been treated successfully with surgery alone, yet a small percentage of patients with advanced disease or adverse histopathological features may require adjuvant radiation therapy and possibly systemic therapy in addition to surgery.

Evaluating immunotherapy prior to surgery

Cemiplimab has been approved for treating metastatic or locally advanced cutaneous squamous-cell carcinoma for which there is no curative local treatment option. In this Phase 2, multicenter, nonrandomized study, researchers evaluated cemiplimab as neoadjuvant therapy in patients with resectable stage II, III or IV cutaneous squamous cell carcinoma. Patients received cemiplimab, administered at a dose of 350 mg every three weeks for up to four doses, before undergoing surgery with curative intent.

A total of 79 patients were enrolled and received neoadjuvant cemiplimab. An independent review found 40 patients (51%) achieved a pathological complete response and 10 patients (13%) achieved a pathological major response after four doses. Though adverse events occurred in 87% of patients, they were mostly very low grade. In the study (NCT04154943), funded by Regeneron Pharmaceuticals and Sanofi, Grade 3 or higher adverse events were observed in 18% of patients.

Advertisement

After surgery, it was at the investigator’s discretion whether to continue immunotherapy for a year, perform surgery or observe the patient. For the investigators at Cleveland Clinic, they opted to observe the patients who had achieved a complete pathological response.

No viable disease

The primary endpoint of the study was pathological complete response where there is no viable disease visible under the microscope. “In time, we’ll be able to report whether these patients required any other cancer-directed therapy in der to maintain no evidence of disease,” says Dr. Geiger.

Reconsidering surgical options

Cemiplimab was originally approved in 2018 for treatment of cutaneous squamous cell carcinoma for which radiation or surgery was infeasible. “My colleagues and I across the country now have a large collection of clinical experience of patients who are older, have large lesions or have comorbidities for whom surgery or radiation is too risky,” says Dr. Geiger. “Now we’re seeing that immunotherapy could be an alternative to surgery and radiation and is a treatment many patients tolerate well.”

Further study needed

Understanding who will and who will not respond to this treatment remains a big question. “We need a way to identify patients for whom immunotherapy is effective and who may not need surgery at all,” said Dr. Geiger. “And equally important, we need to identify patients who are not likely to respond to immunotherapy and who are technically resectable, to avoid delays of a potentially curative surgical approach. That’s the difficult part. What is reassuring is that there is a 50% chance that with just a few doses of immunotherapy, many patients can likely be cured.”

Advertisement

Dr. Geiger and a multidisciplinary team of medical oncologists, surgeons, radiation oncologists and dermatologists serve on a tumor board to review cases of recurrent or aggressive disease of the head and neck. “I’m already seeing patients in clinic where we’re able to recommend this therapy instead of moving straight to surgery.

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad